Heart failure with preserved ejection fraction

Journal of Geriatric Cardiology

Volumn 10, Issue 4, 2013, Pages 369-376

  Rigolli, Marzia ^a,b   Whalley, Gillian A ^a,c  

^a Waitakere Hospital   (New Zealand)

^b UNIVERSITY OF VERONA   (Italy)

^c UNITEC INSTITUTE OF TECHNOLOGY   (New Zealand)

Author keywords

Diastole; Echocardiography; Heart failure; Mortality; Preserved ejection fraction

Indexed keywords

ELDERLY CARE; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE FAILURE; HUMAN; PROGNOSIS; REVIEW;

EID: 84892687123     PISSN: 16715411     EISSN: None     Source Type: Journal    
DOI: 10.3969/j.issn.1671-5411.2013.04.011     Document Type: Review

References (75)

1. McMurray JJ, Adamopoulos S, Anker SD, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012;33:1787-1847.
2. Mosterd A, Hoes AW. Clinical epidemiology of heart failure. Heart 2007;93:1137-1146.
3. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013;62:e147-e239.
4. Hogg K, Swedberg K, McMurray J. Heart failure with preserved left ventricular systolic function: epidemiology, clinical characteristics, and prognosis. J Am Coll Cardiol 2004;43:317-327.
5. Yancy CW, Lopatin M, Stevenson LW, et al. Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) Database. J Am Coll Cardiol 2006;47:76-84.
6. Lee DS, Gona P, Vasan RS, et al. Relation of disease pathogenesis and risk factors to heart failure with preserved or reduced ejection fraction: insights from the Framingham heart study of the national heart, lung, and blood institute. Circulation 2009;119:3070-3077.
7. Bursi F, Weston SA, Redfield MM, et al. Systolic and diastolic heart failure in the community. JAMA 2006;296:2209-2216.
8. Owan TE, Hodge DO, Herges RM, et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006;355:251-259.
9. Hogg K, Swedberg K, McMurray J. Heart failure with preserved left ventricular systolic function; epidemiology, clinical characteristics, and prognosis. J Am Coll Cardiol 2004;43:317-327.
10. Lam CS, Donal E, Kraigher-Krainer E, et al. Epidemiology and clinical course of heart failure with preserved ejection fraction. Eur J Heart Fail 2011;13:18-28.
11. Lenzen MJ, Scholte OP, Reimer WJ, et al. Differences between patients with a preserved and a depressed left ventricular function: a report from the EuroHeart Failure Survey. Eur Heart J 2004;25:1214-1220.
12. Paulus WJ, Tschöpe C, Sanderson JE, et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J 2007;28:2539-2550.
13. Fonarow GC, Stough WG, Abraham WT, et al. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry. J Am Coll Cardiol 2007;50:768-777.
14. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Eur Heart J 2012;33:1787-1847.
15. Lloyd-Jones D, Adams RJ, Brown TM, et al. Heart disease and stroke statistics-2010 update: a report for the American heart association statistics committee and stroke statistics subcommittee. Circulation 2010;121:e1-e170.
16. Jugdutt BJ. Aging and heart failure: changing demographics and implications for therapy in the elderly. Heart Fail Rev 2010, 15:401-405.
17. Borlaug BA, Redfield MM. Diastolic and systolic heart failure are distinct phenotypes within the heart failure spectrum. Circulation 2011;123:2006-2014.
18. Scantlebury DC, Borlaug BA. Why are women more likely than men to develop heart failure with preserved ejection fraction? Curr Opin Cardiol 2011;26:562-568.
19. Krumholz HM, Larson M, Levy D; Sex differences in cardiac adaptation to isolated systolic hypertension. Am J Cardiol 1993;72:310-313.
20. Redfield MM, Jacobsen SJ, Borlaug BA, et al. Age- and genderrelated ventricular-vascular stiffening: a community-based study. Circulation 2005;112:2254-2262.
21. De Simone G, Devereux RB, Chinali M, et al. Sex differences in obesity-related changes in left ventricular morphology: the Strong Heart Study. J Hypertens 2011;29:1431-1438.
22. Foll D, Jung B, Schilli E, et al. Magnetic resonance tissue phase mapping of myocardial motion: new insight in age and gender. Circ Cardiovasc Imaging 2010;3:54-64.
23. Martinez-Selles M, Doughty RN, Poppe K, et al. Gender and survival in patients with heart failure: interactions with diabetes and aetiology. Results from MAGGIC individual patient meta-analysis. Eur J Heart Fail 2012;14:473-479.
24. Pfeffer MA, Braunwald E. Ventricular remodeling after myocardial infarction: experimental observations and clinical implications. Circulation 1990;81:1161-1172.
25. Gaasch WH, Zile MR. Left ventricular structural remodeling in health and disease: with special emphasis on volume, mass, and geometry. J Am Coll Cardiol 2011;58:1733-1740.
26. Jessup M, Brozena S. Heart failure. N Engl J Med 2003;348:2007-2018.
27. Borlaug BA, Kass DA. Ventricular-vascular interaction in heart failure. Cardiol Clin 2011;29:447-459.
28. Little WC, Pu M. Left ventricular-arterial coupling. J Am Soc Echocardiogr 2009;22:1246-1248.
29. Little WC, Cheng CP. Left ventricular-arterial coupling in conscious dogs. Am J Physiol 1991;261:H70-H76.
30. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.
31. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987;316:1429-1435.
32. Hjalmarson A, Goldstein S, Fagerberg B, et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. JAMA 2000;283:1295-1302.
33. Packer M, Fowler MB, Roecker EB, et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation 2002;106:2194-2199.
34. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999;353:9-13.
35. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709-717.
36. Zannad F, McMurray JJ, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011;364:11-21.
37. Cohn JN, Tognoni G. A randomized trial of the angiotensinreceptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345:1667-1675.
38. McMurray JJ, Ostergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-convertingenzyme inhibitors: the CHARM-Added trial. Lancet 2003;362:767-771.
39. Swedberg K, Komajda M, Bohm M, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebocontrolled study. Lancet 2010;376:875-885.
40. Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003;362:777-781.
41. Massie BD, Carson PD, McMurray JD, et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 2008;359:2456-2467.
42. Ahmed A, Rich MW, Fleg JL, et al. Effects of digoxin on morbidity and mortality in diastolic heart failure: the ancillary digitalis investigation group trial. Circulation 2006;114:397-403.
43. Little WC, Zile MR. HFpEF: Cardiovascular abnormalities not just comorbidities. Circ Heart Fail 2012;5:6696-6671.
44. Borlaug BA, Paulus WJ. Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment. Eur Heart J 2011;32:670-679.
45. Paulus WJ, Tschope C, Sanderson JE, et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J 2007;28:2539-2550.
46. Paulus WJ, Van Ballegoij JJ. Treatment of heart failure with normal ejection fraction: an inconvenient truth. J Am Coll Cardiol 2010;55:526-537.
47. Maeder MT, Kaye DM. Heart failure with normal left ventricular ejection fraction. J Am Coll Cardiol 2009;53:905-918.
48. Henein M, Owen A. HFNEF breathlessness: is it really heart failure? Int J Cardiol 2010;143:111-112.
49. Caruana L, Petrie MC, Davie AP, et al. Do patients with suspected heart failure and preserved left ventricular systolic function suffer from "diastolic heart failure" or from misdiagnosis? A prospective descriptive study. BMJ 2000;321:215-218.
50. Ingle L, Cleland JG, Clark AL. Perception of symptoms is out of proportion to cardiac pathology in patients with "diastolic heart failure." Heart 2008;94:748-753.
51. Packer M. Can brain natriuretic peptide be used to guide the management of patients with heart failure and a preserved ejection fraction? The wrong way to identify new treatments for a nonexistent disease. Circ Heart Fail 2011;4:538-540.
52. Paulus WJ, Tschope C, Sanderson JE, et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J 2007;28:2539-2550.
53. Doughty RN, Whalley GA, Walsh HA, et al. CAPRICORN Echo Substudy Investigators. Effects of carvedilol on left ventricular remodeling after acute myocardial infarction: the CAPRICORN Echo Substudy. Circulation 2004;109:201-206.
54. Little WC, Oh JK. Echocardiographic evaluation of diastolic function can be used to guide clinical care. Circulation 2009;120:802-809.
55. Somaratne JB, Whalley GA, Poppe KK, et al. Pseudonormal mitral filling is associated with similarly poor prognosis as restrictive filling in patients with heart failure and coronary heart disease: a systematic review and meta-analysis of prospective studies. J Am Soc Echocardiogr 2009;22:494-498.
56. Bella JN, Palmieri V, Roman MJ, et al. Mitral ratio of peak early to late diastolic filling velocity as a predictor of mortality in middle-aged and elderly adults. The Strong Heart Study. Circulation 2002;105:1928-1933.
57. Schillaci G, Pasqualini L, Verdecchia P, et al. Prognostic significance of left ventricular diastolic dysfunction in essential hypertension. J Am Coll Cardiol 2002;39:2005-2011.
58. Nagueh SF, Appleton CP, Gillebert TC, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. Eur J Echocardiogr 2009;10:165-193.
59. Mogelvang R, Sogaard P, Pedersen SA, et al. Cardiac dysfunction assessed by echocardiographic tissue Doppler imaging is an independent predictor of mortality in the general population. Circulation 2009;119:2679-2685.
60. Al Jaroudi W, Alraies MC, Halley C, et al. Impact of progression of diastolic dysfunction on mortality in patients with normal ejection fraction. Circulation 2012;125:782-788.
61. Meta-analysis global group in chronic heart failure (MAGGIC). The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis. Eur Heart J 2012;33:1750-1757.
62. Ahmed A, Rich MW, Fleg JL, et al. Effects of Digoxin on morbidity and mortality in diastolic heart failure: the ancillary digitalis investigation group trial. Circulation 2006;114:397-403.
63. Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved leftventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003;362:777-781.
64. McMurray JJ, Carson PE, Komajda M, et al. Heart failure with preserved ejection fraction: clinical characteristics of 4133 patients enrolled in the I-PRESERVE trial. Eur J Heart Fail 2008;10:149-156.
65. Campbell TR, Jhund PS, Castagno D, et al. What have we learned about patients with heart failure and preserved ejection fraction from DIG-PEF, CHARM-Preserved, and I-PRESERVE? J Am Coll Cardiol 2012;23:2349-2356.
66. Zile MR, Gottdiener JS, Hetzel SJ, et al. Prevalence and significance of alterations in cardiac structure and function in patients with heart failure and a preserved ejection fraction. Circulation 2011;124:2491-2501.
67. Olsen MH, Wachtell K, Nielsen OW, et al. N-terminal brain natriuretic peptide predicted cardiovascular events stronger than high sensitivity C-reactive protein in hypertension: a LIFE substudy. J Hypertens 2006;24:1531-1539.
68. Persson H, Lonn E, Edner M, et al. Investigators of the CHARM Echocardiographic Substudy-CHARMES. Diastolic dysfunction in heart failure with preserved systolic function: need for objective evidence: results from the CHARM Echocardiographic Substudy-CHARMES. J Am Coll Cardiol 2007;49:687-694.
69. Komajda M, Carson PE, Hetzel S, et al. Factors associated with outcome in heart failure with preserved ejection fraction: findings from the Irbesartan in Heart Failure with Preserved Ejection Fraction Study (I-PRESERVE). Circ Heart Fail 2011;4:27-35.
70. Somaratne JB, Berry C, McMurrey J J V, et al. The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis. Eur Heart J 2012;33:1750-1757.
71. Poppe KK, Squire IB, Whalley GA, et al. Meta-analysis global group in chronic heart failure (MAGGIC). Known and missing left ventricular ejection fraction and survival in patients with heart failure: a MAGGIC meta-analysis report. Eur J Heart Fail 2013;15:1220-1227.
72. Narayanan A, Aurigemma GP, Hill JC, et al. High prevalence of 'unclassifiable' diastolic dysfunction using current criteria. Circulation 2008;118:787.
73. Kitzman DW, Little WC. Left ventricle diastolic dysfunction and prognosis. Circulation 2012;125:743-745.
74. The task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European Society of Cardiology.
75. Komajda M, Hanon O, Hochadel M, et al. Contemporary management of octogenarians hospitalized for heart failure in Europe: Euro heart failure survey II. Eur Heart J 2009;30:478-486.